Clinical Practice Guidelines

Published KDIGO Clinical Practice Guidelines:

• Prevention, Diagnosis, Evaluation and Treatment of Hepatitis C in Chronic Kidney Disease, Published April, 2008

KDIGO currently has three global clinical practice guidelines in nephrology under development:

• Diagnosis, Evaluation, Prevention and Treatment of Chronic Kidney Disease related Mineral and Bone Disorders (CKD-MBD), under the leadership of Drs. Tilman Drüeke and Sharon Moe (Anticipated Publication - 2009)
• Care of the Kidney Transplant Recipient, under the leadership of Drs. Bertram Kasiske and Martin Zeier (Anticipated Publication - 2009)
• Acute Kidney Injury (AKI), under the leadership of Norbert Lameire and John Kellum (Anticipated Publication – 2010)
• Glomerulonephritis, under the leadership of Drs. Daniel Cattran and John Feehally (Anticipated Publication – 2010)

Guiding principles for the KDIGO guideline development process include:

• Scientific and methodological rigor: The process will be evidence-based. The grading of the evidence and recommendations will be guided by the position statement of KDIGO on the grading evidence and recommendations for clinical practice guidelines.
• Interdisciplinary approach: Work Group members will be chosen for leadership in their respective fields, commitment to quality of care and expertise in clinical practice, with due consideration of international representation reflecting the mission statement of KDIGO.
• Independence of Work Groups: The workgroup will have independence and final responsibility in the formulation of recommendations. This will assure an unbiased approach to guideline development, without influence of organizations or industry
• Openness of the guideline development process: Following their initial review by KDIGO Executive Committee and Board of Directors the draft guideline will be subjected to an organizational and peer review process that invites comment from international groups and professionals whom the guideline will affect. Comments submitted at each phase of the review process will be carefully reviewed and considered by the Work Group prior to publication of the final guideline.

The development process will take 18-24 months for each guideline.

We invite you to be part of the clinical practice guideline development by:

• Participating in the guideline development process by registering in the peer review phase of the guideline. (Sign up)
• Submitting your suggestions on future guideline topics and activities that KDIGO should undertake.
  (Take Clinical Practice Guidelines Survey)

We look forward to your participation in this important initiative.

Sincerely,
Garabed Eknoyan
Kai-Uwe Eckardt
KDIGO Co-chairs